About
Cybin, rebranded as Helus Pharma (NASDAQ: HELP | CBOE CA: HELP), is a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders. The company is pioneering a new class of compounds called Novel Serotonergic Agonists (NSAs) — synthetic molecules engineered to activate serotonin pathways believed to foster neuroplasticity and durable improvements in mental health outcomes. Helus Pharma operates two lead drug programs: HLP003 and HLP004 (formerly CYB003/CYB004). CYB004 has completed enrollment in a Phase 2 clinical study for the treatment of Generalized Anxiety Disorder. The company's proprietary drug development platform focuses on creating novel delivery formulations intended to support consistent administration, reduce inter-individual variability in acute effects, and potentially shorten clinical treatment sessions. With over 350 patent applications pending and 100+ granted patents, Helus Pharma maintains a strong intellectual property position. The scientific leadership team brings expertise in neuropsychiatry, oversight of 60+ IND programs, and a track record that includes more than 10 commercially available blockbuster pharmaceutical therapies. The company's work has been featured in major publications including Forbes, TIME, NASDAQ, Business Insider, FiercePharma, and Discover. Helus Pharma is aimed at researchers, clinicians, investors, and mental health advocates interested in the frontier of psychedelic-inspired, second-generation psychiatric therapeutics.
Key Features
- Novel Serotonergic Agonists (NSAs): Proprietary synthetic molecules engineered to activate serotonin pathways and promote neuroplasticity for durable mental health improvements.
- Two Lead Drug Programs: HLP003 and HLP004 are in active clinical development, with Phase 2 enrollment completed for Generalized Anxiety Disorder.
- Proprietary Drug Delivery Platform: Novel delivery formulations designed to support consistent administration and reduce variability in acute effects between patients.
- Robust Intellectual Property Portfolio: Over 350 patent applications pending and 100+ granted patents protecting the company's molecules, processes, and delivery technologies.
- World-Class Scientific Leadership: Team with expertise in neuropsychiatry, 60+ IND programs, and a track record of developing over 10 blockbuster pharmaceutical therapies.
Use Cases
- Investors researching clinical-stage biopharma companies focused on mental health innovation.
- Clinicians and researchers exploring next-generation psychedelic-inspired therapies for anxiety and other psychiatric conditions.
- Patients and advocates seeking information on novel treatment approaches for treatment-resistant mental health disorders.
- Pharmaceutical and biotech professionals evaluating competitive pipelines in the neuropsychiatry space.
- Journalists and media covering the emerging psychedelic medicine and mental health biotech sectors.
Pros
- Strong IP Moat: 100+ granted patents and 350+ pending applications provide significant competitive protection for its pipeline.
- Advanced Clinical Pipeline: Phase 2 studies underway address high-unmet-need conditions like Generalized Anxiety Disorder with a differentiated mechanism of action.
- Experienced Leadership Team: Scientific and regulatory team has overseen 60+ IND programs and brought multiple blockbuster drugs to market.
Cons
- Early-Stage Clinical Risk: As a clinical-stage company, products are not yet approved or commercially available, carrying inherent development and regulatory risk.
- Niche Investor Audience: Psychedelic-inspired therapeutic space may face stigma and regulatory uncertainty that could impact timelines and funding.
Frequently Asked Questions
What is Cybin / Helus Pharma?
Cybin rebranded as Helus Pharma (NASDAQ: HELP). It is a clinical-stage biopharmaceutical company developing novel serotonergic agonists (NSAs) for mental health disorders such as anxiety.
What are Novel Serotonergic Agonists (NSAs)?
NSAs are synthetic molecules designed to activate serotonin pathways in the brain. They are believed to promote neuroplasticity and support durable improvements in mental health outcomes.
What drug programs does Helus Pharma currently have?
Helus Pharma has two lead programs: HLP003 and HLP004. HLP004 (formerly CYB004) has completed enrollment in a Phase 2 study for Generalized Anxiety Disorder.
Is Helus Pharma publicly traded?
Yes. Helus Pharma trades on NASDAQ under the ticker HELP and on CBOE Canada under the same ticker.
How can I invest or learn more about the company?
Investor information, including financials, news, events, and governance details, is available on the Helus Pharma website under the Investors section.
